These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180 [TBL] [Abstract][Full Text] [Related]
3. A family of leukemia inhibitory factor-binding peptides that can act as antagonists when conjugated to poly(ethylene glycol). Fairlie WD; Uboldi AD; Hemmings GJ; Smith BJ; Martin HM; Morgan PO; Baca M Biochemistry; 2003 Nov; 42(45):13193-201. PubMed ID: 14609330 [TBL] [Abstract][Full Text] [Related]
4. The design of antagonist peptide of hIL-6 based on the binding epitope of hIL-6 by computer-aided molecular modeling. Feng J; Li Y; Shen B Peptides; 2004 Jul; 25(7):1123-31. PubMed ID: 15245871 [TBL] [Abstract][Full Text] [Related]
5. A combination of in vitro techniques for efficient discovery of functional monoclonal antibodies against human CXC chemokine receptor-2 (CXCR2). Boshuizen RS; Marsden C; Turkstra J; Rossant CJ; Slootstra J; Copley C; Schwamborn K MAbs; 2014; 6(6):1415-24. PubMed ID: 25484047 [TBL] [Abstract][Full Text] [Related]
6. Chemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys. Hirota M; Murakami I; Ishikawa Y; Suzuki T; Sumida S; Ibaragi S; Kasai H; Horai N; Drolet DW; Gupta S; Janjic N; Schneider DJ Nucleic Acid Ther; 2016 Feb; 26(1):10-9. PubMed ID: 26579954 [TBL] [Abstract][Full Text] [Related]
7. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717 [TBL] [Abstract][Full Text] [Related]
8. Structure-based design and characterization of a Novel IL-6 antagonist peptide. Yang Z; Feng J; Li Y; Hu M; Song L; Yu M; Qin W; Shen B Mol Immunol; 2005 May; 42(9):1015-21. PubMed ID: 15829291 [TBL] [Abstract][Full Text] [Related]
9. Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor. Gupta S; Hirota M; Waugh SM; Murakami I; Suzuki T; Muraguchi M; Shibamori M; Ishikawa Y; Jarvis TC; Carter JD; Zhang C; Gawande B; Vrkljan M; Janjic N; Schneider DJ J Biol Chem; 2014 Mar; 289(12):8706-19. PubMed ID: 24415766 [TBL] [Abstract][Full Text] [Related]
10. Identification of single amino acid residues of human IL-6 involved in receptor binding and signal initiation. Ehlers M; Grötzinger J; Fischer M; Bos HK; Brakenhoff JP; Rose-John S J Interferon Cytokine Res; 1996 Aug; 16(8):569-76. PubMed ID: 8877726 [TBL] [Abstract][Full Text] [Related]
11. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269 [TBL] [Abstract][Full Text] [Related]
12. Active immunization with Tocilizumab mimotopes induces specific immune responses. Yang L; Xing R; Li C; Liu Y; Sun L; Liu X; Wang Y BMC Biotechnol; 2015 Jun; 15():46. PubMed ID: 26033236 [TBL] [Abstract][Full Text] [Related]
13. AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. Akeson AL; Woods CW; Hsieh LC; Bohnke RA; Ackermann BL; Chan KY; Robinson JL; Yanofsky SD; Jacobs JW; Barrett RW; Bowlin TL J Biol Chem; 1996 Nov; 271(48):30517-23. PubMed ID: 8940020 [TBL] [Abstract][Full Text] [Related]
14. Characterization of new anti-IL-6 antibodies revealed high potency candidates for intracellular cytokine detection and specific targeting of IL-6 receptor binding sites. Chouman K; Korioth-Schmitz B; Sack M; Schmitz JE; Pham AT; Fischer R; Barth S; Klockenbring T; Fendel R Eur Cytokine Netw; 2018 Jun; 29(2):59-72. PubMed ID: 30148452 [TBL] [Abstract][Full Text] [Related]
15. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668 [TBL] [Abstract][Full Text] [Related]
16. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes. Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404 [TBL] [Abstract][Full Text] [Related]
18. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells. Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270 [TBL] [Abstract][Full Text] [Related]
19. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663 [TBL] [Abstract][Full Text] [Related]
20. The regenerative activity of interleukin-6. Galun E; Rose-John S Methods Mol Biol; 2013; 982():59-77. PubMed ID: 23456862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]